Not yet recruiting
A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC
NCT07720193· Phase 3· Nanjing Leads Biolabs Co.,Ltd· Source
Contact: xiangyu Ma
Not yet recruiting
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
NCT07920783· Phase 1· Gan & Lee Pharmaceuticals.· Source
Contact: zhuoran Li
Recruiting
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07795346· Phase 3· Antengene Biologics Limited· Source
Contact: Ming Lu
Recruiting
Clinical Study of HS-IT101 Injection in the Treatment of Advanced Renal Cancer(FASTIL-Renal01)
NCT07770802· Phase 1· Hangzhou Huasai Biomedicine Co., Ltd.· Source
Contact: Chuan liang Cui Chief Physician
Active, not recruiting
A Study to Investigate the Effects of Zovaglutide (ZT002 Injection) on QTc Interval in Healthy Adults
NCT07697846· Phase 1· Beijing QL Biopharmaceutical Co.,Ltd· Source
Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Not yet recruiting
A Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based Chemotherapy
NCT07688291· Phase 2· Beijing GoBroad Hospital· Source
Contact: Zhihao Lu
Not yet recruiting
A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases
NCT07593911· Beijing GoBroad Hospital· Source
Contact: Jing Pan, Ph.D
Not yet recruiting
A Phase II Clinical Study of SHR-A1904 Monotherapy in Second-Line or Later Treatment of Advanced Neuroendocrine Carcinoma
NCT07520357· Phase 2· Beijing GoBroad Hospital· Source
Contact: Ming Lu, MD
Recruiting
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
NCT07409428· Phase 3· Hutchmed· Source
Contact: Kai Hu
Recruiting
Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.
NCT06947473· Phase 1/2· Beijing GoBroad Hospital· Source
Contact: ZHOU
Recruiting
Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial
NCT06326008· Phase 1· Beijing GoBroad Hospital· Source
Contact: Tengyu Wang
Recruiting
This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.
NCT07249879· Phase 1· Cancer Institute and Hospital, Chinese Academy of Medical Sciences· Source
Contact: Haifeng Qin, Ph.D.
Recruiting
TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors
NCT07242417· Early phase 1· Beijing GoBroad Hospital· Source
Contact: Qi Changsong Beijing Goabroad Hospital
Recruiting
A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus
NCT07323173· Phase 1· Nanjing Leads Biolabs Co.,Ltd· Source
Contact: lei liu
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380· Phase 3· Eli Lilly and Company· Source
Contact: Chuanliang Cui (principal investigator)
Recruiting
A Study of DEG6498 in Participants With Solid Tumors
NCT07244835· Phase 1· Degron Therapeutics Co.· Source
Contact: Ming Lu, MD
Recruiting
A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases
NCT07167537· Phase 1· Beijing GoBroad Hospital· Source
Contact: Shaocong Miao
Recruiting
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT07111520· Phase 1/2· BioNTech SE· Source
Recruiting
QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma
NCT07049185· Phase 2· Peking University Cancer Hospital & Institute· Source
Contact: Yanshuo Cao
Recruiting
A Clinical Study of GK02 in Malignant Ascites
NCT07378436· Early phase 1· Beijing Geekgene Technology Co., LTD· Source
Contact: Changsong Qi, MD, PhD
Recruiting
A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma.
NCT07099430· Phase 1/2· Nanjing Leads Biolabs Co.,Ltd· Source
Contact: xiangyu Ma
Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657· Phase 1· ArriVent BioPharma, Inc.· Source
Contact: Clinical Trials
Recruiting
A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies
NCT07070323· Phase 1/2· Beijing GoBroad Hospital· Source
Contact: Shaocong Miao
Not yet recruiting
A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma
NCT07014540· Phase 4· Beijing GoBroad Hospital· Source
Contact: Ming Lu
Not yet recruiting
Safety and Effectiveness of Unilateral MR-Guided Focused Ultrasound Thalamotomy for Essential Tremor
NCT07006740· meishanshan· Source
Contact: Ling Chen
Recruiting
A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
NCT06980597· Phase 1· Beijing GoBroad Hospital· Source
Contact: Kai Hu
Recruiting
CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas
NCT07022964· Phase 1/2· Beijing GoBroad Hospital· Source
Contact: Tengyu Wang, Ph.D
Recruiting
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
NCT06892548· Phase 1/2· BioNTech SE· Source
Not yet recruiting
Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.
NCT06922903· Phase 3· Yunhe Pharmaceutical (Tianjin) Co., Ltd· Source
Contact: Dong Yuan
Not yet recruiting
A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment
NCT06922929· Phase 3· Yunhe Pharmaceutical (Tianjin) Co., Ltd· Source
Contact: Dong Yuan
Recruiting
CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
NCT06925464· Phase 1/2· Beijing GoBroad Hospital· Source
Contact: Tengyu Wang, Ph.D
Recruiting
Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
NCT06846996· Daiichi Sankyo· Source
Contact: Principal Investigator
Recruiting
SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
NCT06873659· Phase 1· Qurgen Inc.· Source
Contact: Ming Lu, M.D. (principal investigator)
Recruiting
Phase I Study of OriC902 in Treatment of Advanced HCC
NCT06891742· Phase 1· Peking University· Source
Contact: Changsong Qi
Recruiting
CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)
NCT06822881· Phase 1· Beijing GoBroad Hospital· Source
Contact: Jing Pan
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
NCT06609005· Phase 1/2· Shenzhen Ionova Life Sciences Co., Ltd.· Source
Contact: Chuanliang Cui, MD, PhD
Recruiting
Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia
NCT06890494· Early phase 1· Beijing GoBroad Hospital· Source
Contact: Jing Pan
Recruiting
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
NCT06585514· Phase 1/2· Beijing GoBroad Hospital· Source
Contact: Tengyu Wang
Recruiting
Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
NCT06433609· Phase 2· Beijing GoBroad Hospital· Source
Contact: Wei Zhao
Not yet recruiting
LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma
NCT06472479· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Kai Hu
Recruiting
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
NCT06316856· Phase 1/2· Beijing GoBroad Hospital· Source
Contact: Shaocong Miao
Recruiting
CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction
NCT06389305· Beijing GoBroad Hospital· Source
Contact: Tengyu Wang
Recruiting
Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients
NCT06343090· Beijing GoBroad Hospital· Source
Contact: Tengyu Wang
Recruiting
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies
NCT06316427· Phase 1/2· Beijing GoBroad Hospital· Source
Contact: zhuojun ling
Recruiting
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
NCT06210776· Daiichi Sankyo· Source
Contact: Principal Investigator
Recruiting
A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma
NCT06157827· Phase 1/2· Nanjing Leads Biolabs Co.,Ltd· Source
Contact: xue kong
Recruiting
OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
NCT06182696· Phase 1/2· OriCell Therapeutics Co., Ltd.· Source
Contact: Kai Hu